• 1
    Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin. Liver Dis. 2004; 24: 34962.
  • 2
    Eckle RH, Grundy SM, Zimmet PZ. The metabolism syndrome. Lancet 2005; 365: 141528.
  • 3
    Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005; 43: 50814.
  • 4
    Marchesini G, Bugianesi E, Forlani G et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 91723.
  • 5
    Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 184450.
  • 6
    Fan JG, Zhu J, Li XJ et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 2005; 20: 182532.
  • 7
    Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 4452.
  • 8
    Dam-Larsen S, Franzmann MB, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histological characteristics and prognosis in patients with fatty liver. Scand. J. Gastroenterol. 2005; 40: 4607.
  • 9
    Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2004; 39: 8649.
  • 10
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 141319.
  • 11
    Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129: 3758.
  • 12
    Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease. J. Hepatol. 2006; 44 (Suppl. 2): S401.
  • 13
    Anuurad E, Shiwaku K, Nogi A et al. The new BMI criteria for Asians by the regional office for the western Pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J. Occup. Health 2003; 45: 33543.
  • 14
    Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 256072.
  • 15
    Workshop on Management of Dyslipidemia by Editorial Board of Chinese Journal of Cardiology. [Recommendation of prevention and cure of dyslipidemia.] Zhonghua Xinxieguan Za Zhi 1997; 25: 1678 (in Chinese).
  • 16
    Shaw JE, De Courten M, Boyko EJ, Zimmet PZ. Impact of new diagnostic criteria for diabetes on different populations. Diabetes Care 1999; 22: 7626.
  • 17
    Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a ‘bright’ liver echopattern. Ital. J. Gastroenterol. Hepatol. 1997; 29: 3516.
  • 18
    Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. [Diagnostic criteria of nonalcoholic fatty liver disease.] Zhonghua Gan Zang Bing Za Zhi 2003; 11: 712 (in Chinese).
  • 19
    Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 11321.
  • 20
    Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 104550.
  • 21
    Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 24: 47380.
  • 22
    Fan JG, Fang JW, Lu YS, Qian Y, Cai XB. [A study of the changes of hepatic gene expression in the process of nonalcoholic fatty liver disease development using U230A oligonucleotide microarray.] Zhonghua Gan Zang Bing Za Zhi 2005; 13: 597601 (in Chinese).
  • 23
    Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 216975.
  • 24
    Singh SP. Non-alcoholic fatty liver disease: the unfolding monster? J. Gastroenterol. Hepatol. 2006; 21: 199201.
  • 25
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42: 1328.
  • 26
    Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed? J. Hepatol. 2005; 42: 1214.
  • 27
    Wolf AM, Busch B, Kuhlmann HW, Beisiegel U. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes. Surg. 2005; 15: 22837.
  • 28
    International Diabetes Institute. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne: Health Communications Australia, 2000.